Jamie is a partner with over 14 years of patent experience in the life sciences field. Recognised as a Notable Practitioner in the 2024 edition of IP Stars, his practice focusses on therapeutics and diagnostics, with extensive experience of cell and gene therapy including CRISPR (and other gene editing techniques), antibodies, AAV vectors, and immunoassays.
Jamie is one of the firm’s opposition specialists. He has been involved in some of the most commercially important and legally complex oppositions in the life sciences field at the European Patent Office (EPO). His opposition experience includes high value patents relating to, for example:
-
Base editing
-
Epigenome editing
-
Combination cancer therapy in phase 3 clinical trials
-
AAV vectors for gene therapy
-
Bifunctional fusion protein comprising TGF-β “trap”
-
Antibodies (HUMIRA®, DUPIXENT®)
-
Drug formulations (BYDUREON®)
-
CAR-T for allogeneic transplantation
Another significant part of Jamie’s practice is due diligence and risk management, or “FTO”. He works with investors, start-ups and big-name brands ahead of investment rounds and product launches to advise on infringement risk, validity and risk mitigation strategies.
Jamie is also an expert in rescuing lapsed European patent applications through the EPO’s re-establishment of rights procedure, achieving numerous successes in recent years.
Outside of his day-to-day client work, Jamie had the privilege of presenting to a WHO Expert Advisory Committee on patents and human genome editing as part of the Committee’s consultation process, which led to the publication in July 2021 of the first global recommendations on governance mechanisms for human genome editing. He also provides regular lectures on intellectual property for biochemical engineers at University College London, and for King’s College London on their cell therapy MSc course.
Jamie graduated from the University of Bristol with a first-class degree in biochemistry, which included modules in pharmacology, chemistry and the molecular basis of diseases.